← Back to Search

ATR Kinase Inhibitor

New Treatments for Prostate Cancer

Phase 2
Waitlist Available
Research Sponsored by Canadian Cancer Trials Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have evidence of castrate resistance with biochemical or radiological disease progression
Patients must be ≥18 years of age
Must not have
Patients with specific cardiac conditions, uncontrolled hypertension, or significant liver diseases
Patients with central nervous system involvement unless meeting specified criteria
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a new cancer treatment is effective.

Who is the study for?
Men over 18 with advanced prostate cancer that's resistant to castration and has progressed despite treatment. They must have a life expectancy of at least 6 months, be in good physical condition (ECOG status 0 or 1), and have adequate organ function. Participants need to provide consent for blood tests and tumor sample release, agree to use effective contraception, and be available for follow-up.
What is being tested?
The trial is testing various drugs like Carboplatin, Durvalumab with Tremelimumab, Adavosertib, Savolitinib, Darolutamide, CFI-400945, Ipatasertib on patients whose tumors show specific DNA abnormalities or biomarkers. The goal is to see which drug works best based on these markers.
What are the potential side effects?
Potential side effects include allergic reactions to the drugs or their ingredients; digestive issues due to oral medication absorption problems; liver complications from pre-existing conditions; hormonal changes requiring steroid use; bone density loss if taking bisphosphonates/denosumab.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer is growing despite low testosterone levels.
Select...
I am 18 years old or older.
Select...
My prostate cancer is confirmed and not linked to neuroendocrine tumors.
Select...
My kidneys are working well.
Select...
I am mostly active and my doctors expect me to live 6 months or more.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have heart problems, uncontrolled high blood pressure, or serious liver issues.
Select...
My brain or spinal cord cancer meets certain conditions.
Select...
I have a digestive system condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

7Treatment groups
Experimental Treatment
Group I: novel non-steroidal androgen receptor (AR) antagonistExperimental Treatment1 Intervention
Group II: cMET inhibitorExperimental Treatment1 Intervention
Group III: WEE-1 inhibitor - ARM CLOSEDExperimental Treatment1 Intervention
Group IV: Ipatasertib AKT inhibitorExperimental Treatment1 Intervention
Group V: Durvalumab and Tremelimumab immunotherapyExperimental Treatment1 Intervention
Group VI: Carboplatin platinum based chemotherapyExperimental Treatment1 Intervention
Group VII: CFI400945 PLK4 inhibitor - ARM CLOSEDExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Darolutamide
2018
Completed Phase 2
~100
CFI-400945
2014
Completed Phase 1
~50
Durvalumab and Tremelimumab
2017
Completed Phase 2
~180
Ipatasertib
2017
Completed Phase 3
~3630
Adavosertib
2015
Completed Phase 2
~570
Savolitinib
2024
Completed Phase 2
~190
Carboplatin
2014
Completed Phase 3
~6120

Find a Location

Who is running the clinical trial?

Canadian Cancer Clinical Trials NetworkUNKNOWN
1 Previous Clinical Trials
325 Total Patients Enrolled
BC Cancer FoundationOTHER
18 Previous Clinical Trials
8,359 Total Patients Enrolled
3 Trials studying Prostate Cancer
498 Patients Enrolled for Prostate Cancer
Canadian Cancer Trials GroupLead Sponsor
132 Previous Clinical Trials
69,667 Total Patients Enrolled
9 Trials studying Prostate Cancer
6,703 Patients Enrolled for Prostate Cancer

Media Library

Adavosertib (ATR Kinase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03385655 — Phase 2
Prostate Cancer Research Study Groups: WEE-1 inhibitor - ARM CLOSED, cMET inhibitor, novel non-steroidal androgen receptor (AR) antagonist, CFI400945 PLK4 inhibitor - ARM CLOSED, Ipatasertib AKT inhibitor, Durvalumab and Tremelimumab immunotherapy, Carboplatin platinum based chemotherapy
Prostate Cancer Clinical Trial 2023: Adavosertib Highlights & Side Effects. Trial Name: NCT03385655 — Phase 2
Adavosertib (ATR Kinase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03385655 — Phase 2
~3 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top